The genetic testing firm 23andMe has filed for bankruptcy, another twist in the story of a company that promised a pioneering approach to precision health. Now users are scrambling to delete their personal data, with the future ownership of the firm uncertain. To understand the highs and lows of 23andMe’s journey, Madeleine Finlay hears from the Guardian US tech reporter and editor Johana Bhuiyan, and from Timothy Caulfield, a professor of law at the University of Alberta, who has a special interest in health and biotechnology
Support the Guardian: theguardian.com/sciencepod
About Author
More Stories
Researchers create AI-based tool that restores age-damaged artworks in hours
Australia has ‘no alternative’ but to embrace AI and seek to be a world leader in the field, industry and science minister says
European journalists targeted with Paragon Solutions spyware, say researchers